Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy

24 Jul 2023

Abstract excerpt

Patient-derived autologous chimeric antigen receptor (CAR)-T cell therapy is a revolutionary breakthrough in immunotherapy and has made impressive progress in both preclinical and clinical studies. However, autologous CAR-T cells still have notable drawbacks in clinical manufacture, such as long production time, variable cell potency and possible manufacturing failures. Allogeneic CAR-T cell therapy is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 37554322
DOI: 10.3389/fimmu.2023.1199145

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapyPMID 37554322Read ↗

Allogeneic CAR-T Cells: Engineering Around Host ImmunitySemantic proximity Read ↗

Challenges and opportunities of allogeneic donor-derived CAR T cellsSemantic proximity Read ↗

Off-the-Shelf Chimeric Antigen Receptor T CellsSemantic proximity Read ↗

Toward “off‐the‐shelf” allogeneic CAR T cellsSemantic proximity Read ↗

Recent Advances in Allogeneic CAR-T CellsSemantic proximity Read ↗

Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?Semantic proximity Read ↗

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in GlioblastomaSemantic proximity Read ↗

Chimeric Antigen Receptor T-Cell Therapy: What We Expect SoonSemantic proximity Read ↗

Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapySemantic proximity Read ↗

Trends in cell medicine: from autologous cells to allogeneic universal-use cells for adoptive T-cell therapiesSemantic proximity Read ↗

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapySemantic proximity Read ↗

Overcoming barriers to widespread use of CAR-Treg therapy in organ transplant recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.